November 25, 2026

Company:	Ono Pharmaceutical Co., Ltd.
Representative:	Toichi Takino Representative Director, President and COO (Securities Code: 4528 Prime market, TSE)
Contact:	Ryuta Imura Vice President, Corporate Communications (Phone: +81-6-6263-5670)

Ono Pharma Announces Settlement of U.S. Patent Infringement Litigation with Amgen Concerning OPDIVO® (nivolumab) Intravenous Infusion

- Ono and Bristol Myers Squibb have settled the U.S. patent infringement litigation with Amgen concerning OPDIVO I.V.
- Ono will continue to receive royalties on U.S. sales of OPDIVO I.V. through at least 2036, even after the biosimilar launch.

Osaka, Japan, November 25, 2026 -- Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) today announced that Ono and Bristol Myers Squibb (Headquarters: Princeton, New Jersey, USA; “BMS”) have settled the U.S. patent infringement litigation with Amgen Inc. (Headquarters: Thousand Oaks, California, USA) concerning OPDIVO intravenous infusion (“OPDIVO”), an anti-PD-1 antibody. Under this settlement, Amgen may launch a biosimilar of OPDIVO in the U.S. on or after October 1, 2028.

About Royalties from BMS for OPDIVO in the U.S.

Even after the launch of an OPDIVO biosimilar, Ono will continue to receive royalties from BMS on U.S. sales of OPDIVO through at least 2036. The royalty rate will vary between 2% and 4%, depending on biosimilar penetration in the U.S. market.

The settlement is not expected to have any impact on Ono’s consolidated financial results for the fiscal year ending March 2027.